HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Oral Contraceptive Interest Could Be Price Sensitive, Study Suggests

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

You may also be interested in...



Private Label OTC Giant Stretches For Switch Help

HRA brings needed expertise in OTC switches to Perrigo, which regularly is first to launch generic equivalents for brand switches but its name hasn’t been linked to submitting proposals for making additional drug ingredients available OTC.

Pandemic Makes OTC Access To Daily Oral Contraceptives More Critical, Experts Tell FDA

Nearly 120 researchers, clinicians and advocacy groups have signed a letter to be sent in late August urging FDA to prioritize completion of a review process to make oral contraceptives available OTC.

Oral Contraceptive Switch Advocates Reject User Age As Approval Factor

FDA could soon receive an NDA from non-profit research group Ibis Reproductive Health and HRA Pharma, for an oral contraceptive switch in the US.

Related Content

Topics

UsernamePublicRestriction

Register

RS122617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel